Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00387335 · OUTCOME

Feasibility of Treatment

Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer · Source last updated 2014-07-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
While patient remains on treatment, up to 30 weeks

What was measured

Ability to remain on treatment without dose reduction

Groups in this outcome

Sunitinib -- Cohort A

Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Sunitinib -- Cohort B

Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Sunitinib -- Cohort A15
Sunitinib -- Cohort B7

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Sunitinib -- Cohort A80.0Not reported51.995.7Not reported
Sunitinib -- Cohort B71.4Not reported29.096.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        51.9
        upper Limit
        95.7
        value
        80.0
      2. group Id
        OG001
        lower Limit
        29.0
        upper Limit
        96.3
        value
        71.4
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    2. group Id
      OG001
      value
      7
    units
    Participants
description
Ability to remain on treatment without dose reduction
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Sunitinib -- Cohort A
  2. description
    Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Sunitinib -- Cohort B
param Type
NUMBER
reporting Status
POSTED
time Frame
While patient remains on treatment, up to 30 weeks
title
Feasibility of Treatment
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice